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Abstract
Background: Vein graft disease (VGD) impairs graft patency rates and long-term outcomes after coronary artery
bypass grafting (CABG). DuraGraft is a novel endothelial-damage inhibitor developed to efficiently protect the
structural and functional integrity of the vascular endothelium. The DuraGraft registry will evaluate the long-term
clinical outcomes of DuraGraft in patients undergoing CABG procedures.
Methods: This ongoing multicentre, prospective observational registry will enrol 3000 patients undergoing an
isolated CABG procedure or a combined procedure (ie, CABG plus valve surgery or other surgery) with at least one
saphenous vein grafts or one free arterial graft (ie, radial artery or mammary artery). If a patient is enrolled, all free
grafts (SVG and arterial will be treated with DuraGraft. Data on baseline, clinical, and angiographic characteristics as
well as procedural and clinical events will be collected.
The primary outcome measure is the occurrence of a major adverse cardiac event (MACE; defined as death,
non-fatal myocardial-infarction, or need for repeat-revascularisation). Secondary outcome measures are the
occurrence of major adverse cardiac and cerebrovascular events (MACCE; defined as death, non-fatal
myocardial-infarction, repeat-revascularisation, or stroke), patient-reported quality of life, and health-economic
data. Patient assessments will be performed during hospitalisation, at 1-month, 1-year, and annually thereafter
to 5 years post-CABG. Events will be adjudicated by an independent clinical events committee. This European,
multi-institutional registry will provide detailed insights into clinical outcome associated with DuraGraft.
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Discussion: This European, multi-institutional registry will provide detailed insights into clinical outcome
associated with the use of DuraGraft. Beyond that, and given the comprehensive data sets comprising of
patient, procedural, and graft parameters that are being collected, the registry will enable for multiple
subgroup analyses targeting focus groups or specific clinical questions. These may include analysis of
subpopulations such as patients with diabetes or multimorbid high-risk patients (patient level), evaluation of
relevance of harvesting technique including endoscopic versus open conduit harvesting (procedural level), or
particular graft-specific aspects (conduit level).
Trial registration: ClinicalTrials.gov NCT02922088. Registered October 3, 2016.
Ethics and dissemination: The regional ethics committees have approved the registry. Results will be
submitted for publication.
Keywords: Saphenous vein graft, Vein graft failure, Myocardial infarction, Coronary artery bypass grafting,
Patency, Endothelial damage inhibitor
Background
Surgical revascularisation represents the gold standard for
patients with multivessel coronary artery disease [1]. How-
ever, besides the left internal mammary artery being the
established graft for the left anterior descending (LAD)
territory, the debate about conduit selection for the other
coronary territories is ongoing [2]. Especially for younger
patients, multi- or even total arterial grafting strategies are
recommended, and recent data indicate a significant long-
term benefit when using multiple arterial grafts (ie, right in-
ternal mammary artery or radial artery) [3, 4]. To increase
the use of multiple arterial grafts, the Society of Thoracic
Surgeons recently published the ‘First Clinical Practice
Guidelines on Arterial Conduits [5]. Despite the current ef-
fort on multiarterial grafting, the adoption rate of multiple
arterial conduits in daily clinical practice is rather slow and
is still below 10% due to the technical complexity added to
the CABG procedure [5]. Instead, saphenous vein grafts
(SVGs) remain the most common conduits for coronary ar-
tery bypass grafting (CAGB) procedures [5–9]. In most
cases, SVG conduits are readily available and easy to har-
vest, which is particularly beneficial in urgent or emergency
cases with ongoing ischaemia. Moreover, SVGs are consid-
ered to be more resistant to manipulation during harvest
and anastomosis, and appear less susceptible to vasospasm.
However, compared with arterial conduits, the long-term
patency of SVGs due to vein graft disease (VGD) and con-
secutive failure remains a major issue, substantially impair-
ing long-term clinical outcomes [10, 11]. One-year failure
rates range from 15 to 29%, with at least one graft occluded
graft at 12–18months, and up to 40–50% of failed SVGs at
10 years post CABG [10, 12–14]. Besides general factors
such as the overall progress of a patient’s coronary artery
disease, the quality of the anastomosis and the target vessel,
and postoperative preventive strategies, long-term patency
strongly depends on the overall quality of the SVG conduit
itself. Importantly, damage to the fragile SVG endothelium
appears to be a key promotor for the development and
progress of VGD, stenosis, and complete failure. Therefore,
to best possibly protect the SVG endothelium, several intra-
operative considerations are mandatory. These include
state-of-the-art graft harvesting techniques to reduce trau-
matic injury (ie, no or less-touch techniques), avoidance of
graft distension or over-pressurisation (ie, when assessing
for potential leakages), and, importantly, effective intraoper-
ative storage and preservation to reduce ischaemia reperfu-
sion injury (IRI) of the graft endothelium between harvest
and until completion of anastomosis [10, 11].
To date, (heparinised) saline and autologous whole blood
(AWB) are the most frequently used solutions for intraop-
erative storage and preservation of SVGs [15]. However,
multiple experimental studies and a recently published sub-
analysis of the PREVENT-IV trial have clearly shown that
neither of these solutions sufficiently protects the endothe-
lium [14, 16–20], highlighting a strong clinical need for al-
ternative preservation strategies.
DuraGraft (Somahlution Inc., Jupiter, FL) is a one-time
intraoperative graft treatment that has been developed to
protect against endothelial damage of vascular conduits
during CABG. Several in-vitro studies demonstrated su-
periority for DuraGraft compared with saline or AWB in
preserving the functional and structural integrity of the
conduits’ endothelium [16, 21]. Furthermore, a retrospect-
ive observational study demonstrated that DuraGraft is as-
sociated with reduced long-term complications, including
the occurrence of myocardial infarction and the need for
repeat revascularisation [22]. Despite these encouraging
ex-vivo and clinical data, systematic data validating the
clinical efficacy of DuraGraft to prevent SVGs from the
development of intimal hyperplasia leading to VGD and
subsequent VGF are still pending.
The European, multi-institutional DuraGraft registry
will assess the potential benefit of DuraGraft to effi-
ciently protect against the development and progres-
sion of VGD or VGF in patients undergoing CABG
procedures. The objectives of this registry include the
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long-term assessment of clinical outcomes, including
major adverse cardiac events (myocardial infarction,
death, repeat revascularisation), quality-of-life data,
and health-economic outcomes in patients requiring
CABG procedures and whose vascular grafts are
treated with DuraGraft.
Methods/design
Study design
The DuraGraft registry is a prospective, multicentre,
non-randomised observational study involving 38 cen-
tres from eight countries in Europe (see Additional file 1:
Table S1) for an enrolment target of 3000 patients. A
registry advisory committee has been established to
oversee the study, and an independent clinical events
committee has been set up for adjudication of adverse
events which meet protocol defined outcomes/endpoints
over the course of the study. The registry is registered at
Clinicaltrials.gov under the identifier NCT02922088.
Routine baseline, clinical, and angiographic characteris-
tics as well as procedural and clinical events will be re-
corded using standardised web-based electronic case
report forms. A EuroQol questionnaire will collect pa-
tient information on quality of life. Hospitalisations and
use of healthcare resources after CABG procedures will
be used to determine health-economic outcomes. Patient
assessments will be performed during hospitalisation, at
1 month, 1 year, and annually thereafter to 5 years post-
CABG The study schedule is provided in Table 1.
Patient population and recruitment
Men or women are eligible to enrol in the study if they
meet the following criteria: age ≥ 18 years; undergoing
an isolated CABG procedure or a combined procedure
(ie, CABG plus valve surgery or others) with at least
one (or more) saphenous vein graft(s) or one (or more)
free arterial graft(s) (ie, radial artery or internal mam-
mary artery); and DuraGraft is used during the CABG
procedure. If a patient is enrolled, all free grafts (venous
and/or arterial) will be treated with DuraGraft. Patients
are excluded if they are participating in a medical de-
vice study or have received an investigational study
drug in the month before enrolment.
Consecutive eligible patients are being enrolled at all
38 participating centres for a total of 3000 patients. The
first patient was enrolled on 9 December 2016. The
registry is currently active at 38 sites throughout Europe
and 2700 patients had been enrolled by June 2019. Com-
pletion of enrolment is anticipated in Q3 2019 with the
short term data (30 days) to become available in Q1/
2020, followed by 1-year and 5-year follow up data in
2021 and 2025 respectively.
Intervention
DuraGraft (Somahlution, Jupiter, Florida, USA) is an in-
traoperative treatment that protects against damage to
the structure and function of the vascular endothelium
[22]. It comes in two containers and is formulated into
an ionically and pH-balanced physiological salt solution
containing glutathione, L-ascorbic acid, L-arginine, and
other ingredients that protect the conduit from the dam-
aging effects of ischaemia that occurs during storage and
reperfusion injury during CABG. In brief, after harvest,
every SVG or the free arterial graft (i.e. radial artery, in-
ternal mammary artery) will be carefully flushed with
and stored within DuraGraft prior to anastomosis [23].
Grafting strategy and configuration is left to the discre-
tion of the surgeon.
Data collection and quality assurance
Electronic case report forms will be completed by trained
study coordinator(s) at each site. The following data will
be captured: patient demographics; baseline clinical and
angiographic characteristics; medical history and Euro-
SCORE II [24]; cardiac operative and postoperative data;
graft and anastomosis characteristics (i.e. grafting strategy
and configuration); haemodynamic variables; cardiovascu-
lar medications; patient-reported quality-of-life data; and
health-economics data. A summary of collected parame-
ters can be found in Additional file 1: Table S2.
To maintain confidentiality, a unique identification
number will be allocated to each patient enrolled in the
registry. Anonymised patient-level data will be submitted
to a centralised database (Dendrite Clinical Systems,
Henley-on-Thames, Oxfordshire, UK).
During the follow-up period, patients will be contacted
via mail, email or telephone at 1 month, 1 year, and an-
nually thereafter to 5 years following the CABG proced-
ure to determine whether cardiac-related adverse events
and/or hospitalisations have occurred since the last fol-
low up. For patients who report such hospitalisations,
the study coordinator at the participating site will con-
tact the hospital/practice where the patient was hospita-
lised to request additional information to be entered
into the registry database.
All electronic case report forms will be reviewed and
checked for entry errors, and data queries requiring
clarification will be sent to the study site for resolution.
Source data verification will be performed on a random
sample of patients selected from across all study sites.
Outcome measures
The primary outcome measure is the occurrence of a
major adverse cardiac event (MACE; defined as death,
non-fatal myocardial infarction, or need for repeat
revascularisation) at 1 month, 1 year, and annually
thereafter to 5 years post-CABG. Secondary outcome
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measures are the occurrence of major adverse cardiac
and cerebrovascular events (MACCE; defined as death,
non-fatal myocardial infarction, repeat revascularisa-
tion, or stroke), patient-reported quality of life, and
health-economics data. Definitions for outcome mea-
sures are provided in Table 2.
For the quality-of-life data, patients will be required
to complete the EQ-5D-5 L [25] health status instru-
ment at baseline (before the CABG surgery), at 1 year,
and annually thereafter to 5 years. EQ-5D-5 L com-
prises five questions, each with five levels that repre-
sent five health domains: pain, mood, mobility, self-
care, and activities of daily living [25]. The registry
data will be presented as a measure of overall self-
rated health status.
Statistical design and analyses
The data will be presented using descriptive statistics,
including estimates of event rates, confidence intervals,
and basic cross-tabulations of all data elements.
Registry status
Enrolment is ongoing and is expected to be completed
by Q3/2019 with first data expected to become available
by Q4/2019.
Discussion and expected outcomes
VGD and subsequent failure still represent a major issue
in CABG surgery [10, 11]. Structural and functional
damage of the conduit’s endothelium due to mechanical
harm during harvest and handling, and, importantly, to
ineffective intraoperative preservation appear to be one
of the main triggers of VGD which can be divided into
three mechanisms that may occur at different phases
post-grafting: (a) thrombosis (early phase, within hours
to < 1 month); (b) intimal hyperplasia (intermediate
phase, within months); and (c) atherosclerosis (late
phase, > 12 months) [10].
Duragraft is isotonic, pH-neutral and -buffered and
contains potent antioxidants and a substrate for
endothelial nitric oxide synthase. This biocompatible
milieu with endothelial protective, as well as ischaemic
reperfusion, ischaemia-preventive properties maintains
cell endothelial cell viability and integrity, thereby
inhibiting the perpetual cascade of maladaptive pro-
cesses that start during graft harvesting and storage.
This is in comparison to widely used storage solutions
such as heparinised saline (pH 5.5), whole autologous
blood (pH 8.0) or pH-buffered solutions that merely
prevent changes in pH but do not offer further func-
tionality in maintaining cell integrity.
In this European, multi-institutional registry, the long-
term effect of DuraGraft in patients undergoing CABG
procedures will be investigated. Both early and long-
term data on clinical outcomes, comprising MACE as
well as quality-of-life and health-economic data, will be
prospectively collected, providing detailed insights into
clinical outcome associated with the use of DuraGraft.
The first clinical outcomes from a large, retrospective ob-
servational study in patients undergoing isolated CABG
demonstrated that SVG treatment with DuraGraft was asso-
ciated with a reduced rate of long-term adverse events, in-
cluding myocardial infarction (hazard ratio [HR] 0.55; 95%
confidence interval [CI] 0.41–0.74; p < 0.0001) and the need
for repeat revascularisation (HR 0.65; 95% CI 0.44–0.97; p =
0.037), suggesting that intraoperative treatment with Dura-
Graft may reduce VGD-related adverse events [22]. Taking
these first encouraging data into account, the DuraGraft
registry aims to validate these findings in a prospective man-
ner, and will also further expand the overall clinical experi-
ence with DuraGraft in routine CABG procedures. Beyond
that, and given the comprehensive data sets comprising of
patient, procedural, and graft parameters that are being col-
lected, the registry will also provide a valuable opportunity
for multiple subgroup analyses targeting focus groups or spe-
cific clinical questions. These may include analysis of sub-
populations such as patients with diabetes or multi-morbid
high-risk patients (patient level), evaluation of relevance of
harvesting technique including endoscopic versus open con-
duit harvesting (procedural level), or particular graft-specific
aspects (conduit level). Importantly, the registry will also
Table 1 Study schedule
Screening/ Enrolment CABG/ hospital discharge 1 month Annual follow-up (1–5 years)
Inclusion and exclusion criteria X
Informed consent X
Patient characteristics/medical history X
EuroSCORE II X
Procedural data X
EQ-5D-5 L X X
Health economic data derived X X
MACCE X X X
MACCE Major adverse cardiac and cerebrovascular events (death, non-fatal myocardial infarction, repeat revascularisation, or stroke)
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collect the first clinical data on free arterial grafts (ie, right in-
ternal mammary artery or radial artery) that have undergone
treatment with DuraGraft. In parallel to this registry, a pro-
spective, randomised trial is underway in patients undergoing
isolated CABG with at least two SVGs, which will specifically
evaluate the graft remodelling behaviour after DuraGraft
treatment (NCT02272582 and NCT02774824). DuraGraft-
treated SVGs were randomised against saline-treated con-
duits in the same patient, who were then followed up using
sequential multidetector computed tomography angiography
[23]; the results are eagerly awaited.
In general, when implementing and validating new devices
or treatments, prospectively collected data from large clinical
registries have been established as a useful component in
creating the body of evidence as they substantially differ
from randomised controlled trials (RCTs) in many aspects.
RCTs generally focus on stringently defined patient
cohorts with very narrow inclusion and exclusion criteria
and usually focus on pre-specified time windows rather
than a “real-world” setting. However, as a complement
to RCTs with inherent limitations, large-scale observa-
tional clinical registries offer a great opportunity to
collect data on larger and more diverse patient cohorts
that are representative of patients treated in everyday
clinical practice. In addition, registries offer follow-up
periods that usually extend beyond the classical RCT
windows. Moreover, the relevance of findings can be fur-
ther increased when they project data from different
geographical regions, including clinical sites of various
sizes with different referral, pre- and perioperative strat-
egies in place [26]. Therefore, comprising numerous
small-, mid-, and high-volume European sites, the Dura-
Graft registry is expected to deliver valuable “real-world”
data and insights into current CABG practices from
across Europe. Moreover, the fact that all-comers, either
undergoing isolated CABG or combined procedures (e.g.
valve plus CABG), can be enrolled will further enhance
its clinical relevance. Given its representative nature, the
registry may also serve as a substantial resource for fur-
ther comparison against other ongoing or future studies
in the field of CABG.
Finally, it must be emphasised that despite extensive
evidence of their deleterious effects to the conduits’
endothelium, saline and AWB still represent the most
Table 2 Definitions of registry outcome measures
Outcome Definition
Mortality
Cardiovascular Any of the following criteria:
• Death due to proximate cardiac cause (eg, myocardial infarction, cardiac tamponade, worsening heart failure)
• Death caused by non-coronary vascular conditions such as neurological events, pulmonary embolism, ruptured aortic
aneurysm, dissecting aneurysm, or other vascular disease
• All procedure-related deaths, including those related to a complication of the procedure or treatment for a complication of the
procedure
• All valve-related deaths including structural or non-structural valve dysfunction or other valve-related adverse events
• Sudden or unwitnessed death
• Arrhythmia or cardiac arrest
• Death of unknown cause
Non-
cardiovascular
Any death in which the primary cause of death is clearly related to another condition (e.g. trauma, cancer, suicide)
Myocardial infarction
Periprocedural ≤48 h after the index procedure: absolute rise in cardiac troponin (from baseline) ≥35 times upper reference limit plus ≥1 of the
following criteria:
• New significant Q waves or equivalent
• Flow-limiting angiographic complications
• New “substantial” loss of myocardium on imaging
Spontaneous > 48 h after the index procedure: detection of rise and/or fall in cardiac biomarkers with ≥1 value above the 99th percentile
upper reference limit, together with the evidence of myocardial ischaemia with ≥1 of the following present:
• Symptoms of ischaemia
• Electrocardiographic changes indicative of new ischaemia (new ST-T changes or new left bundle branch block
• New pathological Q-waves in ≥2 contiguous leads
• Imaging evidence of a new loss of viable myocardium or new wall motion abnormality
• Sudden, unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of myocardial ischaemia, and
accompanied by presumably new ST elevation, or new left bundle branch block, and/or evidence of fresh thrombus by
coronary angiography and/or at autopsy, but death occurring before blood samples could be obtained, or at a time before the
appearance of cardiac biomarkers in the blood
• Pathological findings of an acute myocardial infarction
Revascularisation
Endovascular or surgical procedure performed on the DuraGraft-treated venous or arterial graft(s) because of loss of graft
patency
Stroke Neurological deficit documented by physical examination or some form of imaging
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frequently used solutions for intraoperative graft preser-
vation [11, 14, 16–20]. This was highlighted recently in a
study comprising data from 100 top-performing US hos-
pitals, with usage in > 55% of patients [15]. Therefore,
from an educational perspective, the registry may create
further awareness that intraoperative graft preservation
represents an important issue and that there is still an
urgent need for improved graft preservation strategies,
which will be mandatory to achieve the ultimate goal of
enhanced SVG patency, thereby reducing long-term
complications after CABG.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13019-019-1010-z.
Additional file 1: Table S1. List of institutions and principal
investigators. Table S2. List of preoperative parameters that are collected
in the case report forms.
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